Cargando…
Progress toward overcoming hypoxia-induced resistance to solid tumor therapy
Hypoxic tumors are associated with poor clinical outcome for multiple types of human cancer. This may be due, in part, to hypoxic cancer cells being resistant to anticancer therapy, including radiation therapy, chemotherapy, and targeted therapy. Hypoxia inducible factor 1, a major regulator of cell...
Autores principales: | Karakashev, Sergey V, Reginato, Mauricio J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542411/ https://www.ncbi.nlm.nih.gov/pubmed/26316817 http://dx.doi.org/10.2147/CMAR.S58285 |
Ejemplares similares
-
Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2
por: Karakashev, Sergey V., et al.
Publicado: (2015) -
Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
por: Grumetti, Laura, et al.
Publicado: (2022) -
Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia
por: Ramachandran, Shaliny, et al.
Publicado: (2015) -
Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance
por: Kao, Ting-Wan, et al.
Publicado: (2023) -
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021)